Screener
Xenon Pharmaceuticals XENE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Pain programs | 5,582 | 925 | 9,973 | 1,977 |
| Pre-clinical, discovery and other programs | 4,683 | 5,186 | 7,641 | 9,101 |
| Personnel-related expenses | 27,731 | 22,386 | 56,741 | 45,026 |
| Stock-based compensation expense | 16,732 | 13,713 | 33,626 | 25,887 |
| Other research and development costs | 4,642 | 2,600 | 8,843 | 6,025 |
| Other general and administrative costs | 8,025 | 6,014 | 15,826 | 11,545 |
| Interest income | (12,145) | (7,199) | (19,052) | (15,282) |
| Other segment items(1) | (274) | (2,324) | (3,393) | (1,932) |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's stock-based comp?
- Xenon Pharmaceuticals (XENE) reported stock-based comp of $16.73M in Q2 2026.
- How has Xenon Pharmaceuticals's stock-based comp changed year-over-year?
- Xenon Pharmaceuticals's stock-based comp increased by 22.0% year-over-year, from $13.71M to $16.73M.
- What is the long-term trend for Xenon Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's stock-based comp has grown at a 52.2% compound annual growth rate (CAGR), from $10.02M to $53.71M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Xenon Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude